Cisplatin and Continuous Infusion of Fluorouracil Followed by Radiation and Weekly Carboplatin in the Treatment of Locally Advanced Head and Neck Cancer: A Hellenic Cooperative Oncology Group Study

Abstract

Induction chemotherapy followed by radiation has been extensively studied in an effort to improve local control and possibly overall survival of patients with locally advanced head and neck cancer. From June 1989 until May 1991, 39 patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) were treated with 3 cycles of induction chemotherapy, consisting of cisplatin (100 mg/m2 d 1) and fluorouracil (1000 mg/m2 d 2-6) followed by radiation potentiated by weekly administration of carboplatin (60 mg/m2). Surgery was performed in selected patients with residual disease after the combined modality approach. Four cycles of adjuvant chemotherapy with carboplatin (325 mg/m2) and bleomycin (15 u) were administered in those patients who demonstrated a partial response after locoregional treatment. There were 36 men and 3 women with a median age of 56 (range 39-74) years and Karnofsky performance status of 70 (range 60-100). The primary site of the tumor was nasopharynx (8), oropharynx (8), hypopharynx (3), oral cavity (4), larynx (13), paranasal sinus (2), and salivary glands (1). Thirty-two (82%) patients presented with stage IV disease. After the completion of induction chemotherapy, 14 (36%, 95% CI 21-53%) patients achieved a complete response (CR). This CR rate was increased to 56% (95% CI, 42-74%) after locoregional treatment. Main toxicities included nausea/vomiting (56%), leukopenia (40%), anemia (30%), thrombocytopenia (10%), stomatitis (28%), diarrhea (17%), and alopecia (12%). Median relapse-free survival was 18 (1-50) months, median time to progression was 13 (0.3-58.5) months, and median survival 19 (0.3-59) months. Induction chemotherapy with cisplatin and fluorouracil followed by radiation potentiated with carboplatin is feasible. However, this combined modality approach, as applied in the present study, does not appear to yield superior results than those reported with chemotherapy followed by radiation alone.

Long‐term survival data and prognostic factors of a complete response to chemotherapy in patients with head and neck cancer treated with platinum‐based induction chemotherapy: A hellenic co‐operative oncology group study

“…From August 1984 to May 1991, 154 patients with locally advanced HNC were entered in 3 consecutive phase II trials [20][21][22]. Eligibility criteria were the following: histologically confirmed locally advanced non-metastatic (Mo) HNC, measurable or evaluable disease, normal hepatic and renal functions, platelets > 100,00/l, leukocytes >4,000/l, performance status (PS) >40 of Karnofsky's scale, age <75 years, absence of active ischemic heart disease, no prior therapy except a biopsy procedure, and a witnessed informed consent according to our institutional policies.…”

Long-term survival data and prognostic factors of a complete response to chemotherapy in patients with head and neck cancer treated with platinum-based induction chemotherapy: A hellenic co-operative oncology group study

“…From August 1984 to May 1991, 154 patients with locally advanced HNC were entered in 3 consecutive phase II trials [20][21][22]. Eligibility criteria were the following: histologically confirmed locally advanced non-metastatic (Mo) HNC, measurable or evaluable disease, normal hepatic and renal functions, platelets > 100,00/l, leukocytes >4,000/l, performance status (PS) >40 of Karnofsky's scale, age <75 years, absence of active ischemic heart disease, no prior therapy except a biopsy procedure, and a witnessed informed consent according to our institutional policies.…”